Nuvalent, Inc. (NUVL)

NASDAQ: NUVL · IEX Real-Time Price · USD
12.70 0.54 (4.44%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap613.21M
Revenue (ttm)n/a
Net Income (ttm)-35.63M
Shares Out48.28M
EPS (ttm)-3.42
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume74,598
Open12.26
Previous Close12.16
Day's Range11.81 - 12.87
52-Week Range11.81 - 40.82
Betan/a
AnalystsBuy
Price Target42.00 (+230.7%)
Earnings Daten/a

About NUVL

Nuvalent is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We focus our discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. In particular, we focus on “clinically proven” kinase targets. We develop innovative small molecules that are designed to overcome the limitations of those existing therapies. By prioritizing target selectivity, we believe our drug candidates have ...

IndustryBiotechnology
IPO DateJul 29, 2021
CEOJames R. Porter, Ph.D
Employees36
Stock ExchangeNASDAQ
Ticker SymbolNUVL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Nuvalent stock is "Buy." The 12-month stock price forecast is 42.00, which is an increase of 230.71% from the latest price.

Price Target
$42.00
(230.71% upside)
Analyst Consensus: Buy

News

Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhib...

CAMBRIDGE, Mass., Jan. 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announce...

1 week ago - PRNewsWire

Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,...

1 week ago - PRNewsWire

Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results

CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cance...

2 months ago - PRNewsWire

New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC

CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer...

3 months ago - PRNewsWire

Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass., Sept. 8, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cance...

4 months ago - PRNewsWire

Nuvalent Announces Closing of Upsized Initial Public Offering

CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ -- Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announce...

5 months ago - PRNewsWire

Nuvalent Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., July 28, 2021 /PRNewswire/ -- Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announc...

5 months ago - PRNewsWire